PYXS Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (PYXS) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.28 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.0% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Pyxis Oncology, Inc.
Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology